Production (Stage)
Dianthus Therapeutics, Inc.
DNTH
$18.31
-$0.98-5.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.16M | 1.33M | 2.17M | 1.86M | 874.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.16M | 1.33M | 2.17M | 1.86M | 874.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.16M | 1.33M | 2.17M | 1.86M | 874.00K |
| SG&A Expenses | 7.34M | 6.83M | 6.53M | 6.00M | 5.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.34M | 33.24M | 32.07M | 24.07M | 18.72M |
| Operating Income | -33.18M | -31.92M | -29.90M | -22.20M | -17.84M |
| Income Before Tax | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M |
| EBIT | -33.18M | -31.92M | -29.90M | -22.20M | -17.84M |
| EBITDA | -33.15M | -31.89M | -29.88M | -22.18M | -17.82M |
| EPS Basic | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 |
| Normalized Basic EPS | -0.55 | -0.50 | -0.47 | -0.32 | -0.35 |
| EPS Diluted | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 |
| Normalized Diluted EPS | -0.55 | -0.50 | -0.47 | -0.32 | -0.35 |
| Average Basic Shares Outstanding | 35.79M | 35.03M | 34.24M | 34.23M | 25.67M |
| Average Diluted Shares Outstanding | 35.79M | 35.03M | 34.24M | 34.23M | 25.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |